1
Douglas P Kjell: Catalytic stereoselective glycosylation process for preparing 2-deoxy-2,2-difluoronucleosides and 2-deoxy-2-fluoronucleosides. Eli Lilly and Company, Robert A Conrad, David E Boone, June 20, 1995: US05426183 (82 worldwide citation)

A catalytic stereoselective glycosylation process for preparing beta- and alpha-anomer enriched 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides involving reacting an alpha- or beta- anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorocarbohydrate with at least a ...


2
Gerald B Grindey, Larry W Hertel: Method of treating tumors in mammals with 2,2-difluoronucleosides. Eli Lilly and Company, Robert A Conrad, November 7, 1995: US05464826 (81 worldwide citation)

A method of treating susceptible neoplasms in mammals comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound of the formula ##STR1## wherein: R.sup.1 is hydrogen;


3
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, June 11, 1991: US05023269 (65 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


4
Edward E Beedle, David W Robertson, David T Wong: Serotonin antagonists. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, May 7, 1991: US05013761 (60 worldwide citation)

This invention provides a method of selectively antagonizing the 5-HT.sub.1A receptor in mammals by administering aryloxypropanolamines. Novel aryloxypropanolamines are also claimed.


5
F P Carr, Robert D Dillard, Doris E McCullough: Leukotriene antagonists and use thereas. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, August 1, 1989: US04853398 (58 worldwide citation)

This invention provides benzene derivatives which are leukotriene antagonists, formulations of those derivatives, and a method of using those derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.


6
David W Robertson, David T Wong, Joseph H Krushinski Jr: 3-aryloxy-3-substituted propanamines. Eli Lilly and Company, Robert A Conrad, September 11, 1990: US04956388 (56 worldwide citation)

The present invention provides 3-aryloxy-3-substituted propanamines capable of inhibiting the uptake of serotonin and norepinephrine.


7
Marvin E Wildfeuer: 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides. Eli Lilly and Company, Margaret M Brumm, Robert A Conrad, David E Boone, May 28, 1996: US05521294 (48 worldwide citation)

This invention provides novel 1-alkylsulfonyl-2,2-difluoro-3-carbamoyl ribose intermediates and intermediate nucleosides derived therefrom. The compounds are particularly useful in the preparation of 2'-deoxy-2',2'-difluoro-beta-cytidine and other beta anomer nucleosides which are antiviral and anti ...


8
Ta Sen Chou: Stereoselective fusion glycosylation process for preparing 2-deoxy-2,2-difluoronucleosides and 2-deoxy-2-fluoronucleosides. Eli Lilly and Company, Sidney Persley, Robert A Conrad, David E Boone, March 28, 1995: US05401838 (46 worldwide citation)

A stereoselective fusion glycosylation process for prearing beta-anomer enriched 2'-deoxy-2',2'-difluoronucleotides and 2'-deoxy-2'-fluoronucleosides by reacting an alpha-anomer enriched 2-deoxy-2,2-difluorocarbohydrate or 2-deoxy-2-fluorcarbohydrate with at least a 3 molar equivalent of a nucleobas ...


9
Paul L Ornstein: Excitatory amino acid receptor antagonists. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, February 20, 1990: US04902695 (40 worldwide citation)

The present invention provides novel bicyclic derivatives useful as excitatory amino acid receptor antagonists and in treating a variety of associated nervous system disorders.


10
Sherryl L Lifer, Winston S Marshall, Fariborz Mohamadi, Jon K Reel, Richard L Simon, Mitchell I Steinberg, Celia A Whitesitt: Angiotensin II antagonist 1,3-imidazoles and use thereas. Eli Lilly and Company, Robert A Conrad, Leroy Whitaker, December 17, 1991: US05073566 (39 worldwide citation)

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their use for antagonizing angiotensin II receptors in mammals.



Click the thumbnails below to visualize the patent trend.